Clinical Trial

Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 22, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-10-12; most recent amendment 2024-10-21.
Status change: Not Yet Recruiting → Recruiting 2021-05-19
Trial Details
NCT Number NCT04587856
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Myelodysplastic Syndromes
Enrollment 38 participants
Start Date 2021-02-12
Primary Completion 2025-03 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2024-10-22